ARTICLE | Finance
Speeding up DMD
CureDuchenne makes largest investment to speed CRISPR DMD therapy into clinic
March 2, 2017 11:29 PM UTC
Rather than wait for gene editing companies to get around to developing a therapy for Duchenne muscular dystrophy, CureDuchenne Ventures LLC decided to back a leading academic developing CRISPR therapies for DMD to launch Exonics Therapeutics Inc.
On Feb. 27, Exonics debuted with $5 million in seed financing, the largest-ever investment by the venture arm of non-profit CureDuchenne...